CAS 1865733-40-9

Capmatinib hydrochloride

Description:

Capmatinib hydrochloride is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with MET exon 14 mutations. It functions by selectively inhibiting the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. The substance is characterized by its ability to bind to the active site of the MET protein, thereby blocking its signaling pathways that promote cancer cell proliferation. Capmatinib hydrochloride is typically administered orally and is known for its favorable pharmacokinetic profile, including good bioavailability and a manageable side effect profile. The hydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. As with many targeted therapies, monitoring for specific biomarkers is essential for patient selection and treatment efficacy. Overall, Capmatinib hydrochloride represents a significant advancement in targeted cancer therapies, offering hope for patients with specific genetic alterations in their tumors.

Formula: C₂₃H₁₇FN₆O·2HCl·H₂O

Synonyms:

• Capmatinib 2HCl.H2O
• Capmatinib hydrochloride Hydrate
• Capmatinib Hydrochloride Hydrate(INCB28060)
• Capmatinib hydrochloride

Capmatinib 2HCl.H2O

CAS: 1865733-40-9

Capmatinib 2HCl.H2O

Purity: ≥98%

Molecular weight: 503.36g/mol

Ref: 54-BUP10841

Capmatinib 2HCl.H2O

CAS: 1865733-40-9

Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

Formula: C₂₃H₂₁Cl₂FN₆O₂

Purity: 99.77%

Color and Shape: Solid

Molecular weight: 503.36

Ref: TM-T8825

Capmatinib Diydrochloride Monohydrate

CAS: 1865733-40-9

Formula: C₂₃H₁₇FN₆OHClH₂O

Molecular weight: 412.43 : 2(36.5):18.02

Ref: ST-EA-CP-C134001